Research programme: bacterial vaccines - sanofi/Valneva

Drug Profile

Research programme: bacterial vaccines - sanofi/Valneva

Alternative Names: Bacterial vaccines research programme - sanofi/Valneva

Latest Information Update: 12 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell; sanofi pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 31 Aug 2010 Preclinical development is ongoing
  • 14 Jul 2005 Sanofi pasteur has exercised its option for exclusive worldwide commercial rights on certain bacterial vaccine antigens identified in the collaboration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top